1
Clinical Trials associated with Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells(KK Women's & Children's Hospital Pte Ltd.)Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
The purpose of this study is to deliver dual-targeting CAR-T cell therapy (CART 2219.1) as a salvage treatment to patients with relapsed/refractory B-lineage leukaemia in place of stem cell transplant or irradiation.
100 Clinical Results associated with Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells(KK Women's & Children's Hospital Pte Ltd.)
100 Translational Medicine associated with Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells(KK Women's & Children's Hospital Pte Ltd.)
100 Patents (Medical) associated with Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells(KK Women's & Children's Hospital Pte Ltd.)
100 Deals associated with Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells(KK Women's & Children's Hospital Pte Ltd.)